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Abstract
Context—The COMBINE clinical trial recently evaluated the efficacy of medications, behavioral
therapies, and their combinations for the outpatient treatment of alcohol dependence. The costs
and cost-effectiveness of these combinations are unknown and of interest to clinicians and policy
makers.
Objective—To evaluate the costs and cost-effectiveness of the COMBINE interventions at the
end of 16 weeks of treatment.
Design, Setting, and Participants—A prospective cost and cost-effectiveness study of
patients in COMBINE, a randomized controlled clinical trial (RCT) involving 1383 patients with
diagnoses of primary alcohol dependence across 11 US clinical sites.
Interventions—Nine treatment arms, with 4 arms receiving medical management with 16 weeks
of naltrexone (100 mg/d) or acamprosate (3 g/d), both, and/or placebo; 4 arms receiving the same
options as above but delivered with combined behavioral intervention (CBI); and 1 arm receiving
CBI only.
Main Outcomes Measures—Incremental cost per percentage point increase in percent days
abstinent (PDA), incremental cost per patient of avoiding heavy drinking, and incremental cost per
patient of achieving a good clinical outcome.
Results—Based on the mean values of cost and effectiveness, 3 interventions are cost-effective
options relative to the other interventions for all three outcomes: medical management (MM) with
placebo ($409 cost per patient), MM + naltrexone ($671 cost per patient), and MM + naltrexone +
acamprosate ($1003 cost per patient).
Conclusions—This is only the second prospective RCT-designed cost-effectiveness study that
has been performed for the treatment of alcohol dependence. Focusing just on effectiveness, MM
+ naltrexone + acamprosate is not significantly better than MM + naltrexone. However, looking at
cost and effectiveness, MM + naltrexone + acamprosate may be a cost-effective choice, depending
on whether the cost of the incremental increase in effectiveness is worth it to the decision maker.
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Alcohol use is the third leading preventable cause of death,1 and alcohol abuse and
dependence impose significant costs to society. In 1998, the estimated social cost of alcohol
abuse was $184 billion in the United States.2 The sizeable economic and social costs of
alcohol abuse and dependence have prompted considerable interest in developing
interventions to ameliorate these costs and to improve patient functioning. Several
behavioral interventions (e.g., Longabaugh et al.3) and 2 pharmacotherapies, naltrexone and
acamprosate,4,5 have been shown to be efficacious.
Based on evidence for both approaches, the COMBINE Study was designed to examine the
effects of combining behavioral and pharmacotherapies for the treatment of alcohol
dependence.6–9 COMBINE was a multicenter, randomized, controlled clinical trial (RCT)
sponsored by the National Institute on Alcohol Abuse and Alcoholism (NIAAA).
COMBINE was the first study to investigate whether combinations of pharmacotherapies
(naltrexone and acamprosate) with medical management (MM) and a combined behavioral
intervention (CBI) are superior to monotherapy in treating alcohol dependence. A total of
1383 subjects across 11 sites were randomized into 9 treatment groups between January
2001 and the end of treatment in January 2004. Eight of the treatment groups formed a
2×2×2 factorial design. All participants in these groups received MM and were randomized
to receive acamprosate or matching placebo plus naltrexone or matching placebo plus either
CBI or no additional behavioral therapy. The 9th treatment group received only CBI (no
medication or MM). The prespecified primary analyses involved ANOVA-type tests of main
effects and interactions in the 2×2×2 factorial part of the study. Pairwise comparisons
between treatment groups were not prespecified analyses and were not reported in Anton et
al.10
Results for the primary clinical outcomes from COMBINE are available in Anton et al.10
Briefly, in the 16-week treatment period, patients receiving MM with naltrexone, CBI, or
both had better drinking outcomes than those receiving MM but neither naltrexone nor CBI.
The combination of naltrexone and CBI showed no incremental benefit over CBI or
naltrexone alone. Acamprosate showed no evidence of efficacy, with or without CBI or
naltrexone.
Because health care resources are limited, understanding the cost and cost-effectiveness of
the COMBINE interventions is important to help allocate these resources efficiently. In this
paper, we evaluate the cost and cost-effectiveness of COMBINE at the end of 16 weeks of
treatment. The only other RCT-designed cost-effectiveness study11 did not evaluate
combinations of pharmaceutical and behavioral interventions as is done here.
METHODS
Recruitment and Randomization
Participants were recruited by advertisement and from clinical referrals. Each participant
signed an informed consent approved by the institutional review board of each site, and each
site was issued a certificate of confidentiality by NIAAA. Eligibility criteria included (1)
alcohol dependence, determined by Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition (DSM-IV)12 criteria; (2) 4 to 21 days of abstinence; and (3) more than 14
drinks (women) or 21 drinks (men) per week, with at least 2 heavy drinking days (defined as
4 drinks per day for women and 5 drinks per day for men) during a consecutive 30-day
period within the 90 days prior to baseline evaluation. Exclusion criteria included (1) history
of other substance abuse (other than nicotine or cannabis) by DSM-IV criteria in the last 90
days (6 months for opiate abuse) or by urine drug screen, (2) psychiatric disorder requiring
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medication, or (3) unstable medical conditions (e.g., serum liver enzyme levels >3 times the
upper limit of normal). Participants’ median age was 44 years, 71% had at least 12 years of
education, and 42% were married. Ethnic minorities comprised 23% of the sample. In the 30
days prior to randomization, 2.3% of patients were medically detoxified and 7.7% received
inpatient treatment. At baseline, mean percent days abstinent (PDA) was 25.0%, and mean
drinks per drinking day was 12.5.
Cost Estimation
We followed a micro-costing approach to compute the costs of COMBINE therapies from
the treatment provider perspective.13 We estimated the costs of COMBINE from the
provider perspective because this perspective is most relevant to decision makers in best
clinical practice. As described in Zarkin et al.,13 we identified COMBINE activities,
laboratory procedures, and medications that would be needed to implement the therapies in
clinical practice (as opposed to those required to implement a clinical trial research protocol)
and then estimated the cost of each of these activities, updating unit cost estimates to 2007
dollars.
The cost of each COMBINE intervention was determined as the sum of medication, labor,
space, and laboratory costs for each treatment condition. We obtained pharmaceutical costs
for acamprosate and naltrexone from the Federal Supply Schedule (FSS). FSS prices are
negotiated by the Veterans Administration (VA) and are publicly available. These prices are
based on the prices that manufacturers charge their “most-favored” non-federal customers.
The FSS price of acamprosate is $0.64 per 333 mg tab, and the FSS price of naltrexone is
$1.37 per 50 mg tab. This translates into a cost per day of $5.76 for acamprosate and $2.74
for naltrexone, when the naltrexone dose is fully titrated.
To estimate labor costs, we obtained the actual clinician time spent on MM and CBI from
the data coordinating center’s data management system (DMS). These data were collected
prospectively as part of COMBINE. Salary data (including fringe) for all staff involved in
COMBINE interventions were obtained from the cost-effectiveness principal investigators
(PIs) at each site and adjusted to 2007 dollars using the CPI. Time for all other activities
(e.g., staff time to conduct a physical exam) and space use estimates for all relevant
COMBINE activities were obtained from Project Coordinators at 9 of the 11 COMBINE
sites that participated in the cost study. The time spent on COMBINE activities included
time spent preparing for each activity. Data on the number of times staff conducted each
activity were used to calculate a weighted hourly wage rate. For MM and CBI sessions,
labor cost is the product of the actual time spent on each session and the median weighted
hourly wage rate across sites for personnel who conducted these sessions. For all other
activities, for which time was not tracked in the DMS, the labor cost is the product of the
median time across sites spent on the activity and the median hourly wage rate across sites.
Space costs equal the median space costs per activity across sites. See Zarkin et al.13 for
more detail on the cost methodology.
To compute laboratory costs, we identified (with the help of the COMBINE Project
Coordinators and the cost-effectiveness PIs) key laboratory tests from the COMBINE
protocol that are essential if these interventions were implemented in clinical practice. We
then associated each test with a CPT procedure code and obtained baseline cost estimates for
these procedures from the 2005 Resource Based Relative Values Scale (RBRVS),14 which is
used by Medicare to reimburse for services. These costs were adjusted to 2007 dollars using
the CPI.
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The 3 clinical outcomes assessed in our cost-effectiveness analysis are the PDA, the
proportion of patients who did not return to heavy drinking days (≥ 5 standard drinks per
day for men, ≥ 4 for women), and the proportion of patients who maintained a good clinical
outcome15 (abstinent or moderate drinking without problems; with moderate drinking
defined as a maximum of 11 [women] or 14 [men] drinks per week, with no more than 2
days on which more than 3 drinks [women] or 4 drinks [men] were consumed; and problems
defined as endorsing 3 or more items on a standardized questionnaire16 assessing physical,
social, and psychological consequences of drinking.); all these outcomes were measured
through the end of the 16-week treatment period. These outcomes mirror the primary
outcomes from Anton et al.10 As in the main findings paper,10 all outcomes were adjusted
for baseline PDA and clinical site.
Cost-effectiveness Analysis
All interventions were ranked in increasing order of mean cost (C) for each of the 3
effectiveness measures, regardless of the statistical significance of the cost or effectiveness
estimates. Incremental cost-effectiveness ratios (ICERsij), defined as the difference in mean
cost divided by the difference in mean effectiveness (E), (Cj−Ci)/(Ej−Ei), where intervention
j is the next most costly intervention compared to i, were then computed for each
intervention relative to the next most costly option after eliminating treatment options that
are economically dominated by other treatments.17
An intervention is eliminated through strict dominance if there is another intervention that is
less expensive and more effective than the eliminated intervention. An intervention is
eliminated through extended dominance if it has a greater ICER than a more costly
intervention.18 In that case, the cost of achieving a given level of the outcome is lower if the
dominated intervention is eliminated. The non-dominated interventions that remain
comprise the cost-effectiveness frontier (CEF). ICERs are computed and reported for each
intervention on the CEF without regard to the statistical significance of the cost or
effectiveness differences between interventions.
Interventions that are not on the CEF are not cost-effective alternatives and therefore are
excluded from further consideration. Choosing the “optimal” or most cost-effective
intervention from among those remaining on the CEF depends on the perspective from
which the choice is made. Specifically, economic theory suggests that the optimal
intervention is the one with the greatest ICER that is not more than the decision maker’s
intrinsic valuation or willingness to pay (WTP) for an additional unit of the outcome.18
To reflect sampling variability in our cost-effectiveness analysis, we calculated cost-
effectiveness acceptability curves (CEACs) as an alternative to confidence intervals for
ICERs.19,20 The CEACs incorporate the inherent variability of the cost and effectiveness
estimates (i.e., their statistical significance), and they show the probability that an
intervention is the most cost-effective as a function of the policy maker’s intrinsic valuation
or WTP for the clinical outcome. We used nonparametric bootstrap methods to calculate
CEACs for all nine intervention arms (see also UKATT Research Team11; Fenwick et al.20).
Sensitivity Analysis
In a trial such as COMBINE where medications are a critical component of the intervention,
pharmaceutical prices may have a large effect on the cost results. Similarly, as observed in
Zarkin et al.,13 labor costs comprise the largest proportion of activity costs. In our sensitivity
analyses, we evaluated cost and cost-effectiveness analyses with alternative pharmaceutical
prices and with alternative staff wages. Average Wholesale Price (AWP) was used as the
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upper bound for calculating pharmaceutical costs.21 It has also been used in previous cost
and cost-effectiveness studies.22,23 The AWP published in the Red Book is in most cases the
manufacturer’s suggested AWP and does not necessarily reflect the actual AWP charged by
a wholesaler. The AWP is sometimes referred to as a “sticker price” because it is often
higher than the actual price that larger purchasers normally pay. The AWPs for acamprosate
and naltrexone are $0.74 per 333 mg tab (versus $0.64 baseline) and $4.29 per 50 mg tab
(versus $1.37 baseline), respectively. We varied labor costs by using the 25th and 75th
percentiles of sites’ labor costs for performing MM and CBI (versus the median baseline).
We performed 1-way sensitivity analyses in which we first varied pharmaceutical prices
alone (all else the same) and staff wages alone (all else the same as initial values) and then
performed 2-way sensitivity analyses in which we varied both pharmaceutical prices and
staff wages simultaneously.
RESULTS
Table 1 presents the mean costs of each intervention separated into the following categories:
medications, labor costs of MM and CBI, and costs of non-laboratory and laboratory
assessments. Non-laboratory assessments included a medical history, a physical exam, and
other assessments received by every patient and discussed in Zarkin et al.13 With the
exception of the medication costs, there are no significant differences in cost within a
column across the interventions.
The results of the cost-effectiveness analysis for the 3 outcomes are reported in Table 2.
Mean (adjusted) cost and effectiveness represent the results per patient in each of the 9 arms
in COMBINE. MM + placebo is the least expensive intervention ($409 per patient), and
MM + naltrexone + acamprosate + CBI is the most expensive ($1313 per patient). For 2 of
the 3 outcomes, CBI only has the smallest mean effectiveness and MM + naltrexone +
acamprosate has the largest mean effectiveness for all outcomes.
Mean costs and effectiveness are reported for each outcome followed by the results of the
cost-effectiveness analysis. For PDA and the proportion of patients avoiding heavy drinking,
CBI only is strictly dominated from an economic perspective by MM + placebo because the
latter is less expensive and more effective than the former; for the proportion of patients
achieving a good clinical outcome, CBI only is weakly dominated economically. For all
outcomes, MM + placebo is not dominated economically (it is the least expensive
intervention) and is on the CEF. Moving down the column from MM + placebo to more
expensive interventions, MM + naltrexone is less expensive and more effective than all
intervening interventions except for MM + naltrexone + acamprosate; thus, these
intervening interventions are strictly dominated economically. Moving down the column
from MM + naltrexone + acamprosate, the remaining interventions are strictly dominated
economically because they are more expensive and less effective than MM + naltrexone +
acamprosate.
The cost-effectiveness results based on the means for all 3 outcomes show that only 3
interventions are included in the cost-effective choice set: MM + placebo, MM + naltrexone,
and MM + naltrexone + acamprosate (see the shaded interventions in Table 2). The ICER
moving from MM + placebo to MM + naltrexone is $42 per percentage point increase in
PDA, $2847 per patient of avoiding heavy drinking, and $1690 per patient of achieving a
good clinical outcome. The ICER moving from MM + naltrexone to MM + naltrexone +
acamprosate is at least 2.5 times greater for all outcomes: $664 per percentage point increase
in PDA (more than 15 times greater), $8095 per patient of avoiding heavy drinking, and
$7543 per patient of achieving a good clinical outcome.
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Figures 1 through 3 present CEACs. These show the probability that each of the
interventions is the most cost-effective for alternative values of WTP for the outcomes;
WTP represents alternative dollar valuations that may be placed on each outcome by
decisions makers (in this case, treatment providers). Because the WTP for each of these
outcomes will differ and no definitive values have been established for them in the field, we
present alternative WTP values. For PDA (Figure 1), MM + placebo has the highest
probability of being the most cost-effective for low WTP values (below $50); for moderate
values of WTP ($50 to $350), MM + naltrexone has the highest probability of being the
most cost-effective, but that probability decreases as WTP increases and its probability
converges to the probability of MM + placebo + CBI. For high values of WTP, MM +
naltrexone + acamprosate has the highest probability of being the most cost-effective but its
probability never exceeds .4. The other 6 interventions have very small probabilities of
being cost-effective.
For the other 2 outcomes (Figures 2 and 3), MM + naltrexone has the highest probability of
being the most cost-effective for most of the low values of WTP (below $8000), but for
WTP values in excess of $8000, MM + naltrexone + acamprosate has the largest probability
of being the most cost-effective (approximately .50). All the other interventions have
relatively low probabilities of being optimal (less than .20).
Sensitivity Analysis
The cost-effectiveness results are sensitive to the price of naltrexone, but the results are not
sensitive to changes in wages. Under the high pharmaceutical price scenario, naltrexone is
approximately 3 times more expensive than the baseline case; acamprosate is approximately
15% more expensive. For all outcomes, MM + naltrexone is no longer a cost-effective
intervention at the mean values. For PDA and the proportion of patients with good clinical
outcomes, the cost-effective interventions are now MM + placebo, MM + placebo + CBI,
and MM + naltrexone + acamprosate; for the proportion of patients not returning to heavy
drinking, the cost-effective interventions are now MM + placebo, MM + acamprosate, and
MM + naltrexone + acamprosate. ICERs associated with these interventions are similar in
magnitude to the baseline values but are uniformly larger in the sensitivity analysis. The
results of the 2-way sensitivity analysis are the same as the 1-way analysis when
pharmaceutical prices are varied.
COMMENT
This paper presents the first prospective cost and cost-effectiveness study of combining
pharmaceutical and behavioral interventions for alcohol dependence. In addition, it is the
first cost-effectiveness study for alcohol dependence in the United States to be conducted
alongside an RCT (COMBINE). Only 1 previous prospective cost-effectiveness analysis has
been published, and it compared social behavior and network therapy to motivational
enhancement therapy in the UK.11
Our cost and cost-effectiveness analysis is from the perspective of the treatment provider in
best clinical practice rather than from the COMBINE research protocol perspective. This
perspective allows policy makers to apply the results in a real-world clinical setting.
Previous cost-effectiveness literature of pharmaceutical interventions for alcohol
dependence is limited and mainly represents the results of statistical models. No previous
prospective studies exist on the cost and cost-effectiveness of treatment for alcohol
dependence with naltrexone, and many acamprosate studies are based on statistical models
(e.g., Poldrugo et al.24; Palmer et al.25) or represent the health care system perspective (e.g.,
Schadlich and Brecht26). Rychlik et al.27 is a prospective cohort study of the cost-
effectiveness of acamprosate therapy.
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The cost-effectiveness analysis based on the means of cost and effectiveness yields 3 cost-
effective options: MM + placebo, MM + naltrexone, and MM + naltrexone + acamprosate.
Because MM + placebo is the least costly intervention and MM + naltrexone + acamprosate
has the largest mean effectiveness for all 3 outcomes, these interventions are included in the
cost-effective choice set. Based on mean effectiveness alone for PDA, MM + naltrexone and
MM + placebo + CBI are very similar and might be viewed as equivalent in a cost-
effectiveness analysis, but the costs of MM + naltrexone are less making it more attractive
on cost-effectiveness grounds. Clinically, MM + placebo may not be a feasible treatment
option because physicians do not prescribe placebos, which leaves MM + naltrexone and
MM + naltrexone + acamprosate as the 2 viable cost-effective options for all three
outcomes.
The statistical tests in Anton et al.10 were the clinical study’s prespecified tests of main
effects and interactions. These did not find a clinical benefit for acamprosate either as a
main effect or in 2- or 3-way interactions; pairwise comparisons, such as between MM +
naltrexone and MM + naltrexone + acamprosate, were not primary or secondary hypotheses.
In contrast, the prespecified comparisons for the cost-effectiveness analyses involved
looking at each treatment intervention relative to every other intervention in terms of the
joint distribution of costs and effectiveness. Further, the pairwise comparisons presented
here are not formal statistical tests of efficacy; on efficacy alone, MM + naltrexone +
acamprosate is not significantly better than MM + naltrexone.10 However, based on the joint
distribution of cost and effectiveness, MM + naltrexone + acamprosate may be a cost-
effective choice that is selected by decision makers under certain circumstances.
The choice of MM + naltrexone + acamprosate over MM + naltrexone depends on whether
the cost of the incremental increase in mean effectiveness is worth it to the decision maker.
For PDA, MM + naltrexone + acamprosate has only a slightly larger mean effectiveness
than MM + naltrexone (0.5 PDA) but has approximately 50% larger mean cost per patient.
This translates into an ICER for an additional percentage point increase in PDA of $664,
which is an order of magnitude greater than going from MM+ placebo to MM + naltrexone.
If decision makers place a value on increases in PDA equal to or in excess of $664, they
would be willing to pay the incremental cost for MM + naltrexone + acamprosate;
otherwise, they will choose MM + naltrexone. For the proportion of patients who avoid
heavy drinking and the proportion of patients who achieve a good clinical outcome, the
ICERs for MM + naltrexone + acamprosate relative to MM + naltrexone is approximately 3
to 4 times larger (approximately $7500 to $8000 per patient) compared to going from MM +
placebo to MM + naltrexone. If decision makers value increases in mean effectiveness more
than the incremental costs of achieving them, they will choose the interventions with the
greater mean cost and effectiveness.
The CEAC analysis shows that for all three outcomes, the probabilities that any of the
interventions are the most cost-effective are relatively small, except at the very lowest WTP
values. Beyond a WTP of $350 per percentage point increase in PDA, MM + naltrexone +
acamprosate has the largest probability of being the most cost-effective intervention,
although with a relatively small probability of between 0.3 and 0.4. For decision makers
with a relatively high dollar value for PDA who choose MM + naltrexone + acamprosate
because it has the highest probability of being cost-effective, this choice will turn out not to
be the most cost-effective choice 60% to 70% of the time. Similarly, for the proportion of
patients avoiding heavy drinking and the proportion of patients achieving good clinical
outcomes, the probability of MM + naltrexone + acamprosate being the most cost-effective
for large values of WTP is also relatively small, in the range of 0.5 to 0.6
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The low probabilities of being cost-effective even at high values of WTP are caused by 2
key factors: the large number of treatment alternatives (9 versus the usual 2 or 3 alternatives
in most CEA studies), which lowers the probability of choosing any one alternative, all else
equal; and the similarity of many of the mean effectiveness estimates making it difficult to
distinguish between different interventions.
The results are sensitive to the price of naltrexone, which is not unexpected given that the
sensitivity analysis assumed the sticker prices for naltrexone and acamprosate, which
increases the naltrexone price by over 200% (or over 3X) but only increases the price of
acamprosate by 15%. We believe that most providers (and almost certainly large providers)
will have access to naltrexone at the discounted baseline values, but, to the extent that they
do not, our sensitivity results may provide a more accurate perspective of the cost-
effectiveness of the COMBINE intervention.
Our study has 3 primary limitations. First, our cost analysis relies on the judgment of the
cost-effectiveness study PIs as to which activities are primarily research-related and which
would be used in best clinical practice.13 To minimize this issue, we implemented a
consensus approach to achieve agreement on best clinical practice activities. Importantly,
each intervention arm incurs almost the exact same cost for these activities (the exception is
CBI), so any errors in this task will have no differential impact across the arms and will not
affect the cost-effectiveness analysis. Second, although we have attempted to identify
activities that would be part of best clinical practice for the treatment provider perspective,
the treatment regimen we use in our costing algorithm follows the COMBINE protocol. We
expect that patients are seen more frequently in a clinical trial compared to best clinical
practice so we expect our cost estimates to be upper bounds of the actual best practice
treatment costs. Future work may want to look at the cost and cost-effectiveness from other
perspectives, such as the third-party payer or the patient. Third, our cost-effectiveness results
depend on the interventions that were included in the COMBINE study. An alternative set of
interventions provides different comparisons between cost and effectiveness, and different
cost-effectiveness results. Furthermore, the cost-effectiveness results may differ if
alternative clinical and economic endpoints were used (e.g., quality of life, overall
functioning).
In spite of these limitations, our cost study provides an important analysis of the cost and
cost-effectiveness of the COMBINE therapies. As is typical in cost-effectiveness studies, the
choice of the optimal (i.e., most cost-effective) intervention depends on the value placed on
the outcomes by the ultimate decision maker. Furthermore, decision makers may have
different preferences for the 3 outcomes, and their choice of the optimal intervention may
differ by clinical outcome. The similarity of many of the mean effectiveness estimates
suggests that future work that explores moderators of treatment outcome has the potential to
improve the understanding of both treatment outcome and its cost-effectiveness.
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Cost-Effectiveness Acceptability Curve—Percent Days Abstinent
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Cost-Effectiveness Acceptability Curve—Proportion of Patients Who Avoid Heavy
Drinking
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Cost-Effectiveness Acceptability Curve—Proportion of Patients with Good Clinical
Outcomes
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